

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 September 2023 (21.09.2023)



(10) International Publication Number
WO 2023/174948 A2

(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/EP2023/056506

(22) International Filing Date:
14 March 2023 (14.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/269,330 14 March 2022 (14.03.2022) US
PCT/EP2022/058180
28 March 2022 (28.03.2022) EP

(71) Applicant: **TRX BIOSCIENCES LIMITED** [GB/GB];
The Walbrook Building, 25 Walbrook, London EC4N 8AF
(GB).

(72) Inventors: **GOODING, Daniel**; c/o TRx Biosciences Limited,
The Walbrook Building, 25 Walbrook, London EC4N

8AF (GB). **BREW, John**; c/o TRx Biosciences Limited,
The Walbrook Building, 25 Walbrook, London EC4N 8AF
(GB). **BANNISTER, Robin M.**; c/o TRx Biosciences Limited,
The Walbrook Building, 25 Walbrook, London EC4N
8AF (GB).

(74) Agent: **EYRE, David Edward**; 9 St Catherine's Road, Littlehampton BN17 5HS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOSITIONS HAVING IMPROVED BIOAVAILABILITY OF THERAPEUTICS AND USES THEREOF




FIG. 1A

(57) Abstract: The present specification discloses pharmaceutical composition disclosed herein comprises one or more fibrates, one or more glycerolipids, and one or more digestion enhancers. The disclosed glycerolipids comprise one or more hard fats and one or more liquid fats. The disclosed digestion enhancers comprise one or more bile acids, one or more phospholipids, one or more free C₁₄₋₂₄ fatty acids, one or more free C₁₄₋₂₄ fatty acid surfactants, or any combination thereof. The present specification also discloses methods and procedures to formulate the disclosed one or more fibrates into the disclosed pharmaceutical compositions. The present specification further discloses methods and uses of the disclosed pharmaceutical compositions in the treatment of an inflammation and/or neuroinflammation.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*